Immutep Ltd Sponsored ADR Stock

$1.67

0.30% today

Nasdaq, Apr 03, 06:42 pm CET

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Immutep Ltd Sponsored ADR Stock price

$1.67

+0.95 131.98% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.10 5.65%

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$243.08m
Enterprise Value	$145.51m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.28
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-36.10m
Free Cash Flow (TTM) Free Cash Flow	$-29.76m
EPS (TTM) EPS	$-0.22
P/E forward	negative
P/S forward	66.20
EV/Sales forward	39.63
Short interest	3.33%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

5x Buy

100%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Immutep Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	1.52 1.52	20% 20% -
Gross Profit	-1.52 -1.52	20% 20% -
- Selling and Administrative Expenses	33 33	15% 15% -
- Research and Development Expense	- -	- -
EBITDA	-35 -35	16% 16% -
- Depreciation and Amortization	1.52 1.52	20% 20% -
EBIT (Operating Income) EBIT	-36 -36	16% 16% -
Net Profit	-29 -29	8% 8% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Immutep Ltd Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

one day ago

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:

Neutral

GlobeNewsWire

●

2 months ago

Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controls Promising new results ...

Positive

Seeking Alpha

●

2 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials withou...

More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	Marc Voigt
Founded	1987
Website	www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now